Antiparasitic activity of spiro-derivative compound stabilized on multi-walled carbon nanotubes against blastocystis hominis in albino mice

Herein, the medicinal action of a novel spiro-derivative compound ((2R,3R)-4-(4-bromophenyl)-2-(1,7,7-trimethylbicyclo[2,2,1] heptan-2-on-3-yl)-4-oxobutanoic acid, PSp-B) was tested against Blastocystis hominis (B. hominis) with enhancing its curativeness via being immobilized onto multi-walled carbon nanotube (MWCNTs). The infected mice were treated by 50 mg/kg/day drug dosage for five days. The parasitological, physiological and histopathological studies for B. hominis diseased albino mice were explored. Both PSp-B and PSp-B@MWCNTs showed considerable reduction in the number of B. hominis trophozoites in the intestinal content displaying 63.2 % and 76.2 %, respectively. Also, the number of cysts/gm stool in infected mice treated by PSp-B and PSp-B@MWCNTs were highly reduced by 84.7 % and 88.1 %, respectively. The serum Glutathione Reduced (GSH), Lipid Peroxide (MDA) and Nitric Oxide (NO) levels in PSp-B and PSp-B@MWCNTs treated group were ameliorated when compared to negative control group. The histopathological examination of the small intestinal sections in treated groups showed nearly similar character to that of positive control. It is plausible to mention that PSp-B@MWCNTs exhibited privilege Blastocystosis therapeutic performance rather than PSp-B. However, much more studies should be conducted to explore the mechanistic action of these drugs against such and alternative parasites.